Runben Biotechnology Co., Ltd. (SSE: 603193) engages primarily in the research, development, production, and sale of high-end biological reagents and related products for life sciences and medical diagnostics. The company offers core products including nucleic acid extraction and purification reagents, PCR master mixes, reverse transcription kits, real-time PCR detection kits, protein purification reagents, cell culture media and sera, transfection reagents, and fluorescent quantitative PCR instruments; it also provides customized services for molecular diagnostics and biological research consumables. Runben Biotechnology serves research institutions, pharmaceutical companies, clinical laboratories, and biotechnology firms across China and select international markets, with manufacturing and distribution operations concentrated in the Asia-Pacific region. Founded in 2007 and headquartered in Guangzhou, China, the company operates as an independent entity listed on the Shanghai Stock Exchange since 2020. In recent developments within the last two years, Runben Biotechnology expanded its product portfolio through the launch of advanced real-time PCR systems and automated nucleic acid extractors tailored for high-throughput clinical testing, amid growing demand post-pandemic; it also formed strategic partnerships with domestic diagnostic firms to enhance its molecular diagnostics offerings and invested in capacity expansions at its Guangdong facilities to support increased export activities to Southeast Asia.